amikacin has been researched along with guaifenesin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bataillon, V; Lafitte, JJ; Lhermitte, M; Pommery, J; Roussel, P | 1 |
| Bernkop-Schnürch, A; Ellemunter, H; Fontana, S; Griesser, J; Gutierrez, AM; Hetényi, G; Niedermayr, K; Szabó, P | 1 |
1 review(s) available for amikacin and guaifenesin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for amikacin and guaifenesin
| Article | Year |
|---|---|
The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases.
Topics: Amikacin; Anti-Bacterial Agents; Bronchiectasis; Bronchitis; Chronic Disease; Cystic Fibrosis; Humans; Kinetics; Macromolecular Substances; Mucus; Respiration Disorders; Sputum | 1992 |
Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients.
Topics: Amikacin; Bacterial Infections; Cystic Fibrosis; Drug Delivery Systems; Drug Liberation; Emulsions; Humans; Hydrophobic and Hydrophilic Interactions; Lipids; Mucus; Permeability; Pseudomonas aeruginosa; Respiratory Therapy | 2018 |